Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ellis MJ et al. – PIK3CA mutation status did not strongly interact with neoadjuvant endocrine therapy responsiveness in estrogen receptor–positive breast cancer. Nonetheless, as with other recent studies, a favorable interaction between PIK3CA KD mutation and prognosis was detected. The mechanism for the favorable prognostic impact of PIK3CA mutation status therefore remains unexplained.

Related Articles

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09    Relevance Score: 74%

Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening
Journal of Clinical Oncology, 11/09/09    Relevance Score: 72%

Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients
Breast Cancer Research and Treatment, 10/27/09    Relevance Score: 72%

Underweight and breast cancer recurrence and death: A report from the Korean breast cancer society
Journal of Clinical Oncology, 10/08/09    Relevance Score: 72%

Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study
Cancer Epidemiology, Biomarkers & Prevention, 10/01/09    Relevance Score: 72%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address